2. Disease Areas
  3. Cancer Blood or Cardio-cerebrovascular Disease
  4. Leukemia/Lymphoma/Myeloma Blood Disease
  5. Leukemia/Lymphoma/Myeloma
  6. Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

Chronic myelogenous leukemia, BCR-ABL1 positive, is a chronic myeloproliferative neoplasm characterized by the presence of the BCR-ABL1 fusion gene, leading to uncontrolled proliferation of myeloid cells. It commonly affects middle-aged and older adults, presenting with symptoms such as fatigue, weight loss, anemia, night sweats, and splenomegaly, along with neutrophilic leukocytosis. The disease typically begins in a chronic phase, which may progress to an accelerated phase or blast crisis without treatment. Management involves tyrosine kinase inhibitors to target the BCR-ABL1 protein, significantly improving survival, alongside allogeneic stem cell transplantation in select cases.

Chronic Myelogenous Leukemia (21):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-Y0030
    3-Hydroxypicolinic acid 874-24-8 99.92%
    3-Hydroxypicolinic acid is a heterocyclic carboxylic acid ligand and cytotoxin, with a MIC90 of >25 μg/mL against Mycobacterium tuberculosis H37Rv. 3-Hydroxypicolinic acid inhibits the growth of cancer cells and normal fibroblasts. 3-Hydroxypicolinic acid is applicable to research related to chronic myeloid leukemia, human lung adenocarcinoma, and tuberculosis.
    3-Hydroxypicolinic acid
  • HY-160528
    IBG3 98.53%
    IBG3 is a Molecular glue degrader targeting BRD2 and BRD4, with DC50 values of 8.6 pM and 6.7 pM, respectively. IBG3 binds simultaneously to the tandem bromodomains of BRD2/BRD4, induces intramolecular conformational changes, enhances the affinity of BRD2/BRD4 for DCAF16, and promotes ubiquitination and degradation. IBG3 is applicable to the research of chronic myeloid leukemia.
    IBG3
  • HY-N6744
    Chaetoglobosin A 50335-03-0 99.07%
    Chaetoglobosin A is a secondary metabolite and nematicide. Chaetoglobosin A is produced by Penicillium aquamarinium. Chaetoglobosin A targets Filamentous actin in cells, thereby inducing cell cycle arrest, and inhibiting membrane ruffle formation and cell migration. Chaetoglobosin A preferentially induces Apoptosis in chronic lymphocytic leukemia cells. Chaetoglobosin A induces dose- and time-dependent death in J2 larvae of the southern root-knot nematode (Meloidogyne incognita). Chaetoglobosin A can be used in studies related to root-knot nematode disease and chronic lymphocytic leukemia.
    Chaetoglobosin A
  • HY-N0117AR
    (Z)-Indirubin (Standard) 906748-38-7
    (Z)-Indirubin (Standard) is the analytical standard of (Z)-Indirubin (HY-N0117A). (Z)-Indirubin is an isomer of Indirubin (HY-N0117). Indirubin is a bisindole alkaloid with significant anticancer activity against chronic myeloid leukemia.
    (Z)-Indirubin (Standard)
  • HY-N11011
    Withaphysalin A 57423-72-0 98%
    Withaphysalin A is a withanolide compound with anti-inflammatory and antioxidant activities. Withaphysalin A inhibits LPS (HY-D1056)-induced nuclear translocation of NF-κB p65, as well as phosphorylation of STAT3, ERK, JNK and p38 MAPK. Withaphysalin A upregulates the expression of HO-1. Withaphysalin A inhibits LPS-induced production of NO, PGE2, IL-1β, IL-6 and TNF-α. Withaphysalin A downregulates LPS-induced expression of iNOS and COX-2. Withaphysalin A interacts with B-cell activating factor protein (BAFF) to exert inhibitory effects. Withaphysalin A exhibits ELOVL6 inhibitory activity. Withaphysalin A can be used in the research of inflammatory diseases, nephrotic syndrome and chronic myeloid leukemia.
    Withaphysalin A
  • HY-160952
    Cytarabine-daunorubicin 1256639-86-7
    Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia.
    Cytarabine-daunorubicin
  • HY-165532
    SGX393 1030610-86-6
    SGX393 (SGX70393) is a Bcr-Abl kinase inhibitor. SGX393 binds to the active conformation of the kinase domains of both wild-type and T315I mutant Bcr-Abl, thereby inhibiting kinase activity. SGX393 exhibits antiproliferative effects in cells expressing wild-type or T315I mutant Bcr-Abl, and suppresses T315I-driven tumor growth. SGX393 can be used for the research of chronic myeloid leukemia.
    SGX393
  • HY-119126
    PK-3 932331-38-9
    PK-3 is a cancer cell growth inhibitor with microtubule-binding activity. PK-3 binds to tubulin, disrupts the intracellular microtubule network required for mitosis, and induces cell death. PK-3 can be used in research related to chronic myeloid leukemia.
    PK-3
  • HY-183754
    EGFR-IN-213 3115216-45-7
    EGFR-IN-213 is a selective inhibitor of EGFRL858R/T790M/C797S with a human IC50 of 0.48 nM. EGFR-IN-213 acts as an antiproliferative agent, inducing apoptosis and cell cycle arrest, and inhibiting colony formation, cell migration, and tube formation. EGFR-IN-213 can be used for the research of non-small cell lung cancer, chronic myeloid leukemia, gastric cancer, prostate cancer.
    EGFR-IN-213
  • HY-W581798
    Iron(II) sulfate hydrate 17375-41-6
    Iron(II) sulfate hydrate is an iron(II) salt with oral activity, acting as an iron supplier, and is easily oxidized to iron(III) in water. Iron(II) sulfate hydrate induces apoptotic morphological changes in cancer cells, and promotes dose‑dependent iron accumulation in rats. Iron(II) sulfate hydrate can be used in studies of leukemia, breast cancer, iron deficiency, anemia, and restless legs syndrome.
    Iron(II) sulfate hydrate
  • HY-P11705
    PUMA2A
    PUMA2A is a PUMA BH3-only peptide. PUMA2A can be used as a negative control in Cytochrome C release assays and BH3 profiling. PUMA2A can be used in the research of chronic myeloid leukemia.
    PUMA2A
  • HY-N17550
    25-Hydroperoxycycloart-23-en-3β-ol 173740-54-0
    25-Hydroperoxycycloart-23-en-3β-ol is an anticancer, antibacterial, and antimalarial agent. 25-Hydroperoxycycloart-23-en-3β-ol can be isolated from Blepharodon nitidum. 25-Hydroperoxycycloart-23-en-3β-ol exhibits anti-Mycobacterium tuberculosis and antileishmanial activities. 25-Hydroperoxycycloart-23-en-3β-ol shows significant cytotoxic activity against a panel of tumor cell lines (large cell lung cancer, melanoma, colon adenocarcinoma, chronic myelogenous leukemia).
    25-Hydroperoxycycloart-23-en-3β-ol
  • HY-N17609
    Sarsaligates A 1393815-04-7
    Sarsaligates A is a C21-steroid ester with anticancer activity. Sarsaligates A can be used in research related to promyelocytic leukemia, gastric cancer, breast cancer, and pancreatic cancer.
    Sarsaligates A
  • HY-181166
    EGFR-IN-194
    EGFR-IN-194 is a potent EGFR tyrosine kinase inhibitor with an IC50 of 54.3 nM against human EGFR. EGFR-IN-194 induces apoptosis, inhibits migration in cancer cells, selectively promotes invasion in cancer cells, and exhibits antiproliferative effects across multiple cancer cell lines. EGFR-IN-194 can be used for the research of prostate adenocarcinoma, non-small cell lung carcinoma, breast carcinoma, chronic myeloid leukemia.
    EGFR-IN-194
  • HY-180925
    Leu-PEG1-Dasa 3037776-72-7
    Leu-PEG1-Dasa is a potent BCR-ABL PROTAC degrader with a DC50 of 0.48 nM. Leu-PEG1-Dasa uses a single amino acid as the E3 ligand and belongs to a mini-PROTAC, functioning through the N-terminal canonical pathway. Leu-PEG1-Dasa exhibits potent anti-proliferative activity against K562 cells. Leu-PEG1-Dasa can be used for the study of chronic myeloid leukemia (CML).
    Leu-PEG1-Dasa
  • HY-186016
    Arg-PEG1-Dasa 3037776-67-0
    Arg-PEG1-Dasa is a mini-PROTAC targeting BCR-ABL. Arg-PEG1-Dasa induces BCR-ABL degradation (EC50 = 0.85 nM) and shows antiproliferative activity in K562 cells (IC50 = 0.36 nM). Arg-PEG1-Dasa can be used for chronic myeloid leukemia research.
    Arg-PEG1-Dasa
  • HY-180218
    DS-PPE-GW
    DS-PPE-GW is a BCR-ABL ATTEC degrader. DS-PPE-GW connects BCR-ABL and LC3B, thereby tethering BCR-ABL to the autophagosome membrane. DS-PPE-GW shows potent BCR-ABL degradation. DS-PPE-GW has anticancer activity against chronic myeloid leukemia (Pink: LC3B ligand (HY-10542); Blue: BCR-ABL ligand (HY-107447); Black: Linker (HY-W001860)).
    DS-PPE-GW
  • HY-179247
    BCR-ABL1-IN-2
    BCR-ABL1-IN-2 (compound 8) is a potent BCR-ABL1 tyrosine kinase inhibitor. BCR-ABL1-IN-2 exhibits activity in Imatinib (HY-15463) resistant K562/DOX cells with LC50 of 5.29 μM. BCR-ABL1-IN-2 shows no significant toxicity in nontumor cells. BCR-ABL1-IN-2 can be used for chronic myeloid leukemia research.
    BCR-ABL1-IN-2
  • HY-174221
    IMPDH II/HDAC1-IN-1
    IMPDH II/HDAC1-IN-1 (Compound C12) is an orally active, selective dual IMPDH II/HDAC1 inhibitor, with an IC50 of 84.69 nM against hIMPDH II and an IC50 of 81.75 nM against HDAC1. IMPDH II/HDAC1-IN-1 inhibits the proliferation of chronic myeloid leukemia cells. IMPDH II/HDAC1-IN-1 can be used for the research of chronic myeloid leukemia.
    IMPDH II/HDAC1-IN-1
  • HY-120997
    E6 Berbamine 114784-59-7
    E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia.
    E6 Berbamine